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Abstract
Introduction: The prognostic significance of p53 protein expression in early breast cancer remains uncertain, with
some but not all studies finding an association with poorer outcomes. Estrogen receptor (ER) expression is both a
positive prognostic marker and predictive of response to endocrine therapies. The relationship between these
biomarkers is unknown.
Methods: We constructed tissue microarrays (TMAs) from available pathological material from 1113 patients
participating in two randomized clinical trials comparing endocrine therapy alone versus chemo-endocrine therapy
in node-negative breast cancer. Expression of p53 defined as >10% positive nuclei was analyzed together with
prior immunohistochemical assays of ER performed at central pathological review of whole tumor sections.
Results: ER was present (i.e. >1% positive tumor cell nuclei) in 80.1% (880/1092). p53 expression was significantly
more frequent when ER was absent, 125/212 (59%) than when ER was present, 171/880 (19%), p <0.0001. A
significant qualitative interaction was observed such that p53 expression was associated with better disease-free
survival (DFS) and overall survival (OS) among patients whose tumors did not express ER, but worse DFS and OS
among patients whose tumors expressed ER. The interaction remained significant after allowance for pathologic
variables, and treatment. Similar effects were seen when luminal and non-luminal intrinsic subtypes were
compared.
Conclusions: Interpretation of the prognostic significance of p53 expression requires knowledge of concurrent
expression of ER. The reason for the interaction between p53 and ER is unknown but may reflect qualitatively
different p53 mutations underlying the p53 expression in tumors with or without ER expression.
Trial registration: Current Controlled Trials ACTRN12607000037404 (Trial VIII) and ACTRN12607000029493 (Trial IX).
Introduction
The p53 tumor suppressor protein, encoded by the
TP53 gene, is a transcription factor that when activated
as part of the cellular stress response, regulates suites of
genes involved in cellular processes including the cell
cycle, apoptosis, and senescence [1]. Mutations in TP53
are amongst the commonest genetic alterations in
human cancer, but unlike other tumor suppressors,
TP53 is not usually inactivated through deletion or trun-
cating mutations [2]. Instead, it commonly undergoes
mono-allelic missense mutations affecting the DNA
binding domain, leading to the production of a protein
that lacks DNA binding activity but remains capable of
binding to, and hence dominantly inactivating, wild-type
p53. Some TP53 mutations also result in the acquisition
of new oncogenic properties, and it is unclear whether
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any medium, provided the original work is properly cited.loss of wild-type function, gain of oncogenic function, or
their combined effects, account for the oncogenicity of
these mutations [1,2]. Interpretation of many experi-
ments addressing this issue is complicated by the recent
identification of multiple p53 isoforms, which arise from
alternative splicing and the presence of an internal pro-
moter [3]. The principal isoforms differ in the domain
responsible for oligomerization, but are identical
through the transactivation and DNA binding domains
in which many TP53 mutations occur.
Wild-type p53 protein is rapidly degraded, except
under conditions of cellular stress. TP53 mutations are
often, although not always, associated with the produc-
tion of a stable protein that is readily detectable by
immunohistochemistry (IHC) of cancer cells [1,2]. IHC
detection of p53 protein is therefore loosely, but imper-
fectly, associated with mutations in TP53. Some studies
assessing p53 status using either IHC or mutational ana-
lysis have concluded that TP53 mutation is associated
with poor prognosis, but other authors have reported no
impact of TP53 mutation on outcome in early breast
cancer, and the evidence is not sufficiently strong for
p53 status to be recommended as a marker in routine
clinical practice [4]. Studies of women treated with a
variety of chemotherapeutic regimens, or hormonal
therapy suggest that p53 status may be predictive of
response to therapy [5,6]. However, until recently few
large studies have either considered, or been able to
effectively control for, treatment effects. Retrospective
analyses of randomized clinical trials, using either IHC
measurement of p53 expression (CALB 9344) or TP53
gene sequencing (BIG 02-98), have identified a signifi-
cant association with a worse prognosis in patients trea-
ted with adjuvant doxorubicin and cyclophosphamide or
doxorubin but no significant association with response
to taxanes [7,8]. Similarly, a prospective clinical trial
(EORTC 10994/BIG 1-00) found that TP53 status was
not predictive of response to taxane-based therapy [9].
The different methods used to assess p53 status have
both advantages and disadvantages. Direct identification
of mutations by sequencing has the advantage of pin-
pointing the specific aberration, but is not currently
applicable to clinical practice because of its expense,
technical difficulty, and likely reduced sensitivity in the
routine setting. In addition, it may mis-classify some
functionally equivalent genomic alterations, where TP53
is inactivated indirectly. Functional assessment of p53
activity in yeast offers a distinction between inactivating
and other mutations [10,11]. Several laboratories have
attempted to develop gene signatures of p53 inactivation,
w h i c hc a np o t e n t i a l l yb em e a s u r e du s i n gaP C R - b a s e d
test [12-14]. However, these assays are not immediately
practical for routine diagnosis, and some of these signa-
tures are potentially measures of subtype rather than p53
status, since mutations in TP53 are more frequent in
tumors lacking estrogen receptor (ER) expression
[15-17], in tumors of basal-like, HER2 and luminal B sub-
types [18,19], tumors showing stem-cell like transcrip-
tional patterns [20] and in those with high proliferative
fraction [21]. IHC detection of p53 protein mis-classifies
some TP53 mutations, and instances where TP53 is inac-
tivated through deletion or truncation, or where persis-
tent cellular stress leads to sustained expression of p53
protein. However, it does have the advantage of ready
transfer into clinical practice, if studies in large, well-
characterized cohorts provide good evidence of potential
utility as a biomarker. Since the material available for the
present study was limited to tissue micro-arrays, IHC
was the most suitable available method.
Evidence for cross-talk between ER and p53 pathways
at several levels suggests that the impact of TP53 muta-
t i o nm a yb ea f f e c t e db yt h ep r e s e n c eo fE R .F i r s t ,E Ri s
a p53 target and conversely estrogen treatment induces
p53 expression, although it has also been reported to
increase the cytoplasmic localization of p53, thereby
functionally inactivating it [22-24]. Second, p53 is
required for hormonal protection against carcinogen-
induced mammary cancer in rodents [25,26]. Finally, the
ER and p53 proteins physically interact, leading to
repression of their transcriptional activity and protection
of p53 from degradation [27-29]. However, other
authors have concluded that the dominant interaction is
via ER and p53 binding their cognate response elements
in cis to cooperatively regulate p53-responsive genes
[30]. Simultaneous allowance for p53 and ER in survival
analysis of patients with early breast cancer, where the
presence of ER is a favorable prognostic factor [31-34],
and predicts the efficacy of endocrine therapies [31], has
yielded conflicting results. Some authors report indepen-
dent adverse prognostic significance of ER-negativity
and p53 expression [15,35] while more recently, differ-
ent p53 gene signatures have been associated with dis-
parate prognosis and response to cytotoxic therapy in
ER-positive and ER-negative disease [12].
As a step towards addressing some of these issues, we
have explored the relationship between ER expression
and p53 expression detected by immunohistochemistry
on prognosis in the context of large prospective rando-
mized clinical trials. In the present study we have exam-
ined available pathological material from International
Breast Cancer Study Group (IBCSG) Trials VIII and IX,
comparing endocrine adjuvant therapy alone versus
combined modality chemo-endocrine therapy in patients
with node-negative early breast cancer. This revealed a
qualitative interaction between ER and p53 expression,
such that p53 expression was prognostically adverse in
patients whose tumors expressed ER, but favourable in
those whose tumors lacked ER expression.
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Trials and patients
The designs of IBCSG Trials VIII and IX have been
described in detail elsewhere [36,37]. Briefly, from 1990
to 1999 in Trial VIII, 1,063 pre- and peri-menopausal
women with node-negative early breast cancer were ran-
domly assigned to endocrine therapy with 24 months of
goserelin alone, six cycles of chemotherapy with classical
cyclophosphamide, methotrexate and 5-fluorouracil
(CMF) or a sequence of 6 cycles of CMF followed by 18
months of goserelin. Similarly, from 1988 to 1999 in
Trial IX, 1,669 eligible postmenopausal women were
randomly assigned endocrine therapy with 5 years of
tamoxifen 20 mg daily or three cycles of CMF followed
by tamoxifen to complete 5 years therapy. In each trial,
randomization was stratified according to locally-deter-
mined ER status. Institutional review boards reviewed
and approved the protocols, and informed consent was
required according to the criteria established within the
individual countries. Patient follow-up, vital status and
date of any relapse or recurrence are recorded in the
IBCSG database. Median follow-up from randomization
in Trial VIII is 12 years [36] and in Trial IX is 13 years
[37]. IBCSG Trials VIII and IX were conducted from
1988 to 1999. Ethical approval was obtained in partici-
pating countries according to national regulations. The
IBCSG Independent Data Monitoring Committee
reviewed the trials periodically. All patients included in
the analysis provided consent to participate in the trials.
The study was reviewed and approved by the IBCSG
Biological Protocols Working Group.
Pre-existing pathological data
Central review of immunohistochemical expression of
ER in whole sections has been documented [38,39].
The data presented in these published reports is incor-
porated in a cumulative IBCSG database, which has
been used to classify ER status in the present study.
Similarly, the central review assessment of tumor size,
Bloom and Richardson grade [39], and peri-tumoral
vascular invasion, as previously described [40], were
used for the present study. HER2 was considered as
positive if 3+ by IHC at central assessment or ampli-
fied by fluorescent in situ hybridisation (FISH) per-
formed on the tissue microarrays (TMAs) (HER2: C17
ratio > 2.0). There is debate about the threshold at
which tumors should be considered positive for ER
[41,42]. Following IBCSG practice [39] and the recom-
mendations of the American Society of Clinical Oncol-
ogy and the College of American Pathologists [43], and
b e f o r ea n yd a t aa n a l y s i s ,w ed e f i n e dac u t - p o i n tt o
identify ER as present if at least 1% of cells showed ER
staining on immunohistochemistry.
Tissue microarrays
Available tissue blocks from 1,493 patients randomized
to IBCSG Trials VIII (593 patients) and IX (900
patients) were sent from the IBCSG Pathology Office to
the Cancer Research Program, Garvan Institute of Medi-
cal Research, Sydney, Australia for construction of tissue
TMAs. The TMAs were produced using the MTA-1
Manual Tissue Arrayer and a 1.0 mm needle to biopsy
tumor tissue identified by examination of hematoxylin
and eosin (H&E)-stained slides from a standard histolo-
gical block. Three representative cores were taken from
each donor block and deposited in the recipient array
block. Each array in Trial VIII comprised 108 (9 ± 12)
cores representing about 32 patients. Arrays from Trial
IX comprised 96 cores (8 ± 12) representing about 28
patients. An asymmetric template was employed for
core orientation. Cores of renal tissue (± 6) were ran-
domly placed within each array to act as orientation
markers when scoring. Normal breast cores taken from
reduction mammoplasties (± 6) were also placed on
each array to allow comparison between immunohisto-
chemical staining in morphological normal breast and
invasive breast carcinoma. Details of numbers of
patients randomized and those analyzed in the present
study are given in the REMARK Diagram (Figure 1) and
in Table 1. Briefly, after exclusion of ineligible patients
and those from non-compliant institutions, TMAs were
prepared from 1,220 patients (Trial VIII, 450; Trial IX,
770). Staining for p53 as described below was success-
fully performed on TMAs from 1,113 patients (Trial
VIII, 417; Trial IX, 696). Comparison of patients
assessed for p53 and those not so assessed is presented
in Table 1. Centrally reviewed ER was unavailable for 21
patients (Trial VIII, 11; Trial IX, 10) leaving a study
cohort for the present analysis of 1,092 patients (Trial
VIII, 406; Trial IX, 686).
TMA staining
Four-μms e c t i o n sw e r eb a k e di na no v e na t6 3 ° Cf o r2
hours followed by rehydration in graded ethanols, fol-
lowed by water. Antigen retrieval was performed by
boiling in a water bath for 30 minutes at pH 9.0 using
Dako antigen retrieval solution (S2367, Dako, Denmark).
All additional steps were performed on a Dako autostai-
ner: p53 monoclonal antibody (clone DO-7 Dako, Den-
mark) was incubated at 1:200 dilution for 30 minutes at
room temperature, following standard blocking proce-
dures with 3% hydrogen peroxide for 5 minutes. Detec-
tion involved Envision labeled polymer-horseradish
peroxidise (HRP) anti-mouse antibody (Dako, Denmark)
which was added for 30 minutes at room temperature,
followed by diaminobenzidine (DAB)+ chromogen
(Dako, Denmark) for 10 minutes. Slides were then
Coates et al. Breast Cancer Research 2012, 14:R143
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Page 3 of 12Trial VIII 
Randomized 
1,111 
Excluded 
Assigned No Treatment arm  46 
Non-compliant Institution 2 
Definitive trial population 
1,063 
Goserelin   346 
CMF     360 
CMF Ö Goserelin   357 
TMA analyzed for HER2 
FISH, cyclin D1 & p53 
417 (39%) 
Goserelin   137 
CMF     134 
CMF Ö Goserelin   146 
Trial IX 
Randomized 
1,715 
Excluded 
Ineligible 39 
Non-compliant Institution 7 
Definitive trial population 
1,669 
Tamoxifen   846 
CMF Ö tamoxifen   823 
TMA analyzed for  
HER2 FISH, cyclin D1 & p53 
696 (42%) 
Tamoxifen   352 
CMF Ö tamoxifen   344 
Figure 1 Remark diagram showing patients randomized to the parent clinical trials and those included in the present cohort for
analysis of p53 expression. CMF, cyclophosphamide, methotrexate, 5-fluorouracil; FISH, fluorescent in situ hybridisation; HER, human epidermal
growth factor receptor 2.
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mounted. Isotype-matched non-specific immunoglobulin
was substituted for the primary antibody as the negative
control. A p53 positive breast carcinoma was used as
the positive control.
P53 scoring
All scoring was performed by an experienced breast
pathologist blinded to all clinical and outcome informa-
tion. Maximum nuclear staining > 10% (any intensity)
was considered positive, as employed in most studies
using this antigen. Data from the scoring assessment of
p53 on the TMAs were entered into, the data handling
program (Cansto) at the Garvan Institute of Medical
Research, Sydney.
Statistical analysis
Data on baseline characteristics and follow-up were
extracted from the IBCSG clinical and pathological data-
base and merged with the p53 data obtained from
TMAs. The trial endpoint was disease-free survival
(DFS), defined as the length of time from the date of
randomization to any invasive breast cancer relapse
(including ipsilateral or contralateral breast recurrence),
the appearance of a second non-breast malignancy, or
death, whichever occurred first, or was censored at the
date of last follow-up. Overall survival (OS) was defined
as the length of time from randomization to death from
any cause, or was censored when last known alive. OS
and DFS were estimated using the Kaplan-Meier
method and compared using the logrank test. The asso-
ciation of covariates and of interactions between vari-
ables with OS and DFS was assessed using proportional
hazard models. Since similar effects and interactions
were observed separately for each trial (data not shown)
the definitive analyses included all available patients.
Multivariate DFS and OS analyses were stratified by
trial, using SAS software version 9.2. Proportional
hazards assumptions were checked using martingale
residuals. All P-values are two-sided.
Results
Characteristics of analyzed patients compared to other
trial participants
Blocks available for this study were those with residual
tumor after routine pathology, central review and the
Table 1 Patient characteristics by analysis cohort
Trial VIII Trial IX Pooled Trials
p53 Analyzed Not analyzed Analyzed Not analyzed Analyzed Not analyzed
Number of patients 417 646 696 973 1,113 1,619
Median age (range) 46 45 61 60
(26 to 58) (22 to 56) (42 to 77) (34 to 81)
ns ns
ER status, n
Absent 84 101 128 137 212 238
> = 1% 322 360 558 516 880 876
Missing 11 185 10 320 21 505
ns
1 ns
Tumor size, n
0 to 1 cm 27 99 65 136 92 235
> 1 to 2 cm 206 321 333 450 539 771
> 2 cm 182 217 280 352 462 569
Missing 2 9 18 35 20 44
P < 0.0001 P = 0.01
Tumor grade, n
52 94 85 160 137 254
1 171 286 304 447 475 733
2 168 179 248 261 416 440
3 26 87 59 105 85 192
Missing P = 0.002 P = 0.0004
10-year DFS 71.3% 76.0%
P = 0.15
2
67.6% 75.5%
P = 0.10
10-year OS 86.4% 87.4%
P = 0.44
81.1% 83.8%
P = 0.65
1P-values compare distribution of non-missing values between analyzed and non-analyzed cohorts; ns, not significant.
2DFS and OS P-values based on logrank
comparison of entire curves. n, number of patients; DFS, disease-free survival; OS, overall survival.
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Page 5 of 12conducting of previous translational research studies
using whole tumor sections [39,44,45]. Thus the 1,113
patients with p53 results available for this project were
more likely to be those with more advanced tumors
than those not included. This is reflected in the signifi-
cantly higher proportion in larger primary tumor size
categories and with higher Bloom and Richardson grade
in patients available from both trials. There was no sig-
nificant difference in age distribution or the presence of
ER and the trends to worse DFS and OS were not statis-
tically significant (Table 1).
Impact of p53 status and ER, and their interaction on
outcome
Data on p53 status were available in 1,113 patients and
for centrally reviewed ER status in 1,092 of these. P53
positivity was more common among patients with absent
ER expression (125/212, 59%) than among those expres-
sing ER (171/880, 19%, P < 0.0001). In univariate analyses
the overall slight negative impact of p53 expression on
DFS was not significant (Figure 2A). In the presence of
ER expression, the adverse effect of p53 staining was
more marked while in the absence of ER, p53 expression
was associated with better DFS (Figure 2B and 3).
A statistically significant interaction was present
between p53 status and ER (P = 0.004), as shown in
Table 2. The statistical significance of the interaction per-
sisted for both DFS and OS in further models allowing
for significant pathological variables, and for treatment
allocation and its interaction with ER status (Table 2).
We found no evidence of interaction between p53
expression and the relative efficacy of the various endo-
crine or chemo-endocrine therapies used in the trials
(data not shown), indicating that in our studies p53
expression was not a predictive marker for the efficacy of
adding CMF chemotherapy to endocrine adjuvant ther-
apy. Martingale residuals reflected no violations of pro-
portionality apart from the ER variable. Tumors lacking
ER are known to exhibit higher initial failure rates [46].
The classification of ER presence (if at least 1% of
tumor cells showed ER staining on IHC) was defined
prior to any data analysis. Exploration of an alternative
ER-positive cut-point based on staining of at least 10%
of cells [41], resulted in reclassification of 45 patients
with ER staining levels of 1 to 9%, and this materially
reduced the clarity of the interaction with p53 status
(DFS interaction hazard ratio (HR) 1.76, P = 0.04, OS
interaction HR 1.68, P = 0.11).
Reflecting the effect of ER expression, a similar dichot-
omy of impact of p53 expression was seen when
patients were divided into luminal and non-luminal sub-
types based on IHC expression of ER, progesterone
receptor and Ki67, as well as the detection of HER2 by
IHC (3+) or FISH [47] (Figure 3).
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Logrank P = 0.034



Figure 2 Disease-free survival by p53 expression (≥ 10%) at
12-year median follow-up.( A) All analysed patients. (B) Patients
whose tumors expressed estrogen receptor (ER). (C) Patients whose
tumors did not express ER.
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Page 6 of 12Variable P53 Pos P53 Neg
Hazard Ratio
95% CI P Value Hazard Ratio
Events/Total (%)
P53 and outcome by ER and Intrinsic Subtype
0.25 0.5 0.75 1 1.25 1.5 1.75
p53 Pos
better
p53 Pos
worse
Disease-free Survival
All Patients 108/303 (35.6) 272/810 (33.6) 1.12 (0.89,1.39) 0.34
By ER
ER Present 65/171 (38.0) 230/709 (32.4) 1.29 (0.98,1.70) 0.069
ER Absent 40/125 (32.0) 39/87 (44.8) 0.62 (0.40,0.97) 0.035
By Intrinsic Subtype
Luminal A 10/36 (27.8) 102/334 (30.5) 0.87 (0.45,1.67) 0.68
Luminal B 54/129 (41.9) 112/313 (35.8) 1.29 (0.93,1.78) 0.13
HER2 nonluminal 9/34 (26.5) 12/26 (46.2) 0.46 (0.19,1.09) 0.078
Triple Negative 29/86 (33.7) 26/56 (46.4) 0.64 (0.38,1.09) 0.10
Overall Survival
All Patients 59/303 (19.5) 168/810 (20.7) 0.95 (0.71,1.28) 0.75
By ER
ER Present 32/171 (18.7) 135/709 (19.0) 1.03 (0.70,1.52) 0.86
ER Absent 25/125 (20.0) 32/87 (36.8) 0.48 (0.29,0.81) 0.0063
By Intrinsic Subtype
Luminal A 5/36 (13.9) 56/334 (16.8) 0.77 (0.31,1.93) 0.58
Luminal B 28/129 (21.7) 75/313 (24.0) 0.95 (0.62,1.47) 0.83
HER2 nonluminal 6/34 (17.6) 10/26 (38.5) 0.35 (0.13,0.98) 0.046
Triple Negative 18/86 (20.9) 21/56 (37.5) 0.52 (0.27,0.97) 0.040
Figure 3 Forest plots of hazard ratios for disease-free and overall survival by p53, estrogen receptor (ER) expression and intrinsic
subtype.
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Page 7 of 12Table 2 Interaction between presence of estrogen receptor (ER) and p53 expression
Hazard ratio 95% Confidence interval P-value
Disease-free survival models
1
p53 univariate (positive vs negative) 1.128 0.902, 1.410 0.3
ER univariate (present vs absent) 0.850 0.663, 1.090 0.2
Without interaction
p53 1.044 0.815, 1.339 0.7
ER 0.866 0.660, 1.138 0.3
With interaction
p53 0.606 0.390, 0.942 0.03
ER 0.606 0.431, 0.851 0.004
Inter p53/ER
2 2.152 1.278, 3.623 0.004
With pathological variables
3
p53 0.575 0.368, 0.896 0.01
ER 0.747 0.517, 1.081 0.12
Inter p53/ER 1.968 1.156, 3.352 0.01
Grade 1 1.00 Reference 0.0009
4
Grade 2 1.463 1.018, 2.104
Grade 3 1.988 1.362, 2.903
Vascular invasion
5 1.314 1.040, 1.661 0.02
With pathological and treatment variables
p53 0.581 0.373, 0.906 0.02
ER 0.957 0.608, 1.507 0.85
Inter p53/ER 1.941 1.139, 3.307 0.01
Grade 1 1.00 Reference 0.0009
Grade 2 1.458 1.014, 2.097
Grade 3 1.988 1.361, 2.904
Vascular Invasion 1.305 1.033, 1.650 0.03
Tmt Endocrine only
6 1.688 1.081, 2.636 0.02
Inter Tmt/ER
7 0.595 0.360, 0.984 0.04
OS models
p53 univariate 0.985 0.731, 1.326 0.9
ER univariate 0.667 0.493, 0.901 0.008
Without interaction
p53 0.783 0.561, 1.092 0.15
ER 0.599 0.430, 0.836 0.003
With interaction
p53 0.460 0.273, 0.777 0.004
ER 0.434 0.295, 0.638 <0.0001
Inter p53/ER 2.350 1.225, 4.507 0.01
With pathological variables
p53 0.426 0.252, 0.719 0.001
ER 0.498 0.325, 0.763 0.001
Inter p53/ER 2.293 1.187, 4.433 0.01
T < = 1 cm 1.00 Reference 0.003
T >1 to 2 cm 1.858 0.932, 3.706
T > 2 cm 2.682 1.340, 5.368
Grade 1 1.00 Reference 0.11
Grade 2 1.578 0.957, 2.604
Grade 3 1.759 1.041, 2.973
Vascular invasion 1.309 0.971, 1.764 0.08
With pathological and treatment variables
p53 0.427 0.253, 0.723 0.002
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The present study is unusual in demonstrating a signifi-
cant qualitative interaction between two biological mar-
kers. Detectable p53 expression was associated with
better prognosis in patients whose tumors did not
express ER but with worse prognosis if ER was
expressed. This interaction appeared robust in the two
trials examined and was independent of other pathologic
features and of treatment. However, this and the similar
interaction between p53 status and intrinsic subtype (as
assessed by IHC) were unexpected and therefore require
confirmation in large independent data sets for which
p53 status is known to be available, such as that recently
described by Lara et al. for the Cancer and Leukemia
Group B [7], the EORTC 10994/BIG 1-00 trial described
by Bonnefoi et al. [9], or the BIG 2-98 trial described by
Francis et al. [48].
If confirmed, such an interaction might at least par-
tially explain the earlier disparate reports of the prog-
nostic significance of p53 staining viewed in isolation.
Based on our exploratory analysis of a higher ER cut-
point we suggest that any confirmatory study should
look primarily at ER-present (IHC > 1% staining) versus
ER-absent staining. Our observation that the interaction
is most clearly seen with an ER cut-point reflecting ER
expression versus absence of expression may explain the
failure to observe such an interaction in earlier small
studies which typically used a higher ER cut-point
[15,16,35].
If the interaction between ER and p53 as markers of
p r o g n o s i si sb i o l o g i c a l l yr e a l ,i t sb a s i si sc u r r e n t l y
unclear, although there is evidence for functional rela-
tionships between p53 and ER that affect mammary
oncogenesis and/or response to tamoxifen. In genetically
engineered mice, p53 heterozygosity leads to increased
mammary epithelial proliferation, decreased apoptosis
and eventual development of pre-neoplastic mammary
lesions [49]. These responses are all enhanced in the
presence of deregulated ER expression [49]. A direct
interaction between p53 and ER has been described to
inhibit p53-responsive transcriptional activation in
mammospheres, but this response is antagonised by
tamoxifen, suggesting a mechanism that could contri-
bute to a better response to tamoxifen in women with
wild-type p53 [50]. Our observation that p53 positivity
is associated with a worse prognosis in women treated
with tamoxifen in the context of a randomised clinical
trial is consistent with this idea.
TP53 mutations are not only more common among
breast cancers not expressing ER, and among the basal-
like and HER2 molecular subtypes, which typically lack
ER expression [18] but also tend to be different in type
[12]. Mutations are non-randomly distributed along the
p53 domains [5,51]. Different p53 mutations have been
described as carrying differing adverse prognostic signifi-
cance [5,8,17]. It is possible that p53 staining by IHC
seen in tumors not expressing ER reflects mutations
that are not disabling, or are less disabling, to cell
homeostasis than those responsible for p53 IHC staining
in tumors expressing ER.
As well as the well-studied canonical p53 protein, nor-
mal breast tissue expresses the p53b and p53g isoforms,
which arise from alternative splicing and differ at the
carboxy-terminus [3]. Most TP53 mutations will result
in changes in all three isoforms, and there are as yet no
reagents for IHC that distinguish between them. How-
ever, different patterns of isoform expression are appar-
ent in breast cancer: p53b mRNA expression is
associated with ER expression, while p53g mRNA
expression is associated with TP53 mutation [52]. Each
has been detected by PCR in 36 to 37% of breast can-
cers, but only 19% were found to express both [52].
Since the antibody used in this study recognises all
three isoforms and the p53b protein isoform is more
Table 2 Interaction between presence of estrogen receptor (ER) and p53 expression (Continued)
ER 0.604 0.355, 1.028 0.06
Inter p53/ER 2.280 1.179, 4.409 0.01
T < = 1 cm 1.00 Reference 0.002
T > 1 to 2cm 1.929 0.965, 3.856
T > 2 cm 2.762 1.378, 5.536
Grade 1 1.00 Reference 0.11
Grade 2 1.573 0.954, 2.594
Grade 3 1.749 1.034, 2.957
Vascular invasion 1.295 0.961, 1.745 0.09
Tmt endocrine only 1.574 0.931, 2.659 0.09
Inter Tmt/ER 0.666 0.363, 1.222 0.19
1Stratified by trial.
2Interaction term reflects cases with both expression of p53 and presence of ER.
3Tumor size was not significant and was dropped from the
disease-free survival model.
4Peritumoral vascular invasion at central pathology review.
5P-values for multi-level variables (tumor size and grade) reflect overall
significance.
6Treatment allocation endocrine only (goserelin in trial VIII, tamoxifen in trial IX) without chemotherapy.
7No interaction was seen between p53
status and the presence or absence of chemotherapy (data not shown). Inter, interaction (as detected by statistical analysis); Tmt, treatment allocation.
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p53 IHC positivity represents a different spectrum of
isoforms in cancers expressing, or not expressing ER.
The isoforms are differently regulated and may have dif-
ferent functions [3]. In particular, the physical interac-
tion between ER and p53 occurs via the carboxy-
terminal domain, which differs in sequence between the
different p53 isoforms [29]. Although patients expres-
sing mutant p53 but not p53g have been shown to have
a particularly poor prognosis, those expressing mutant
p53 and p53g have a good prognosis, indistinguishable
from patients expressing wild-type p53 [52]. This com-
plexity in the prognostic impact of TP53 mutations may
contribute to the interaction with ER observed here.
Future studies should attempt to clarify this relation-
ship by use of material from patients with p53 staining
to ascertain the nature of the p53 mutations involved
and examine their prognostic significance. Meanwhile it
seems prudent to encourage independent validation of
the current data in other large randomized clinical trials
and to interpret the prognostic significance of IHC
detection of p53 in the context of ER expression.
Conclusions
IHC detection of p53 protein in early breast cancer
loosely reflects the presence of p53 mutations but its
prognostic significance is inconsistently reported. In
patients with node-negative breast cancer who partici-
pated in International Breast Cancer Study Group Trials
VIII and IX we show that the relationship between p53
expression and DFS and OS was dependent on ER status.
Among patients whose tumors expressed ER, p53 expres-
sion was associated with inferior DFS and OS, whereas
p53 expression was associated with better DFS and OS in
patients whose tumors did not express ER. The interac-
tion was statistically significant, and remained so in mod-
els including other pathological variables. Similarly, p53
was associated with worse prognosis among patients with
luminal tumor subtypes but better prognosis among
those with triple-negative or HER2-positive subtypes.
Interpretation of the prognostic significance of p53 stain-
ing requires consideration of ER status.
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